Literature DB >> 12451014

Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke.

Hua Cai1, Zongming Li, Andreas Goette, Fernando Mera, Clegg Honeycutt, Kristian Feterik, Josiah N Wilcox, Samuel C Dudley, David G Harrison, Jonathan J Langberg.   

Abstract

BACKGROUND: In the arterial endothelium, laminar flow and cyclical stretch induce expression of NO synthase (NOS). We hypothesized that atrial fibrillation (AF) causes a downregulation of atrial endocardial NOS expression and NO* production. Because NO* has antithrombotic properties, this may contribute to thromboembolism in AF. METHODS AND
RESULTS: In pigs, AF was produced with rapid atrial pacing at 600 bpm for 1 week, whereas controls had atrial pacing at 100 bpm. All animals production from freshly isolated tissue was measured by a NO*-specific microelectrode. Left atrial basal and stimulated NO* production was decreased in AF by 73% and 71% (P<0.01). Endocardial NOS expression, determined by Western analysis, was also significantly decreased by 46%. Expression of the prothombotic protein plasminogen activator inhibitor 1 (PAI-1) is known to be regulated by NO* and was increased in the left atrium by 1.8-fold in AF (P<0.05). NO* concentration was decreased in the left atrial appendage, although NOS expression was not affected. Neither NOS concentration, NO* levels, nor PAI-1 expression were altered in the aortas or right atria of animals with AF.
CONCLUSIONS: AF is associated with a marked decrease in endocardial NOS expression and NO* bioavailability and an increase in PAI-1 expression in the left atrium. These data suggest that organized atrial contraction is needed to maintain normal endocardial expression of NOS. It is likely that loss of this antithrombotic enzyme contributes to the thromboembolic phenomena commonly observed in AF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12451014     DOI: 10.1161/01.cir.0000039327.11661.16

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  79 in total

Review 1.  Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective.

Authors:  Stanley Nattel; Jordi Heijman; Liping Zhou; Dobromir Dobrev
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

2.  Attenuated response of L-type calcium current to nitric oxide in atrial fibrillation.

Authors:  Nadiia Rozmaritsa; Torsten Christ; David R Van Wagoner; Hannelore Haase; Johannes-Peter Stasch; Klaus Matschke; Ursula Ravens
Journal:  Cardiovasc Res       Date:  2013-12-12       Impact factor: 10.787

Review 3.  [New antiarrhythmic drugs for therapy of atrial fibrillation: II. Non-ion channel blockers].

Authors:  M Hammwöhner; A D'Alessandro; D Dobrev; P Kirchhof; A Goette
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

Review 4.  Cardioembolic Stroke.

Authors:  Hooman Kamel; Jeff S Healey
Journal:  Circ Res       Date:  2017-02-03       Impact factor: 17.367

Review 5.  Pulling on my heartstrings: mechanotransduction in cardiac development and function.

Authors:  Margaret E McCormick; Ellie Tzima
Journal:  Curr Opin Hematol       Date:  2016-05       Impact factor: 3.284

6.  Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial.

Authors:  C N Pellegrini; E Vittinghoff; F Lin; S B Hulley; G M Marcus
Journal:  Heart       Date:  2009-01-28       Impact factor: 5.994

Review 7.  Antioxidant therapies for the management of atrial fibrillation.

Authors:  Tong Liu; Panagiotis Korantzopoulos; Guangping Li
Journal:  Cardiovasc Diagn Ther       Date:  2012-12

Review 8.  The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias.

Authors:  Shahriar Iravanian; Samuel C Dudley
Journal:  Heart Rhythm       Date:  2008-03-04       Impact factor: 6.343

9.  Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxidative stress and adhesion molecules in patients with persistent atrial fibrillation.

Authors:  Andreas Goette; Alessandra D'Alessandro; Alicja Bukowska; Siegfried Kropf; Christian Mewis; Christoph Stellbrink; Jürgen Tebbenjohanns; Christian Weiss; Uwe Lendeckel
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

10.  Advanced age, low left atrial appendage velocity, and factor V promoter sequence variation as predictors of left atrial thrombosis in patients with nonvalvular atrial fibrillation.

Authors:  Dmitry A Zateyshchikov; Alexey N Brovkin; Dimitry A Chistiakov; Valery V Nosikov
Journal:  J Thromb Thrombolysis       Date:  2010-08       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.